Hexarelin

Hexarelin is a synthetic growth hormone (GH) secretagogue from the ghrelin-mimetic class. It was first studied in the early 1990s as a potent, multi-route stimulator of GH release Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man+1. Unlike some newer agents, Hexarelin also commonly raises ACTH, cortisol, and prolactin, making its hormonal profile broader than GH-only stimulation The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.

Early clinical research tested Hexarelin via intravenous, subcutaneous, intranasal, and oral administration, confirming activity by all routes but with varying efficiency Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Human endocrine studies have used it to probe pituitary GH reserve in both healthy adults and patients with GH deficiency The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency+1. More recent reviews highlight its continued interest as a performance-enhancing peptide, despite limited human outcome data for physique or recovery endpoints The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.

Hexarelin binds and activates the ghrelin receptor (GHSR1a), a G-protein coupled receptor found on pituitary somatotrophs and in the hypothalamus The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1. This triggers a calcium-dependent signaling cascade that causes pulsatile GH secretion Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

Its GH-releasing effect depends partly on hypothalamic growth hormone-releasing hormone (GHRH): blocking GHRH reduces but does not abolish the response Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects to those observed in young adults. Hexarelin also synergizes with GHRH, producing larger GH pulses than either agent alone Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

Unlike more selective secretagogues like ipamorelin, Hexarelin reliably stimulates ACTH, cortisol, and prolactin in humans, especially with repeated dosing The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+2. This broader endocrine activation is a key distinction in its pharmacological profile The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Repeated daily injections can alter 24-hour hormone profiles, sustaining GH elevation but also raising prolactin and adrenal steroids, which has implications for long-term use Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.

In human studies, Hexarelin consistently increases serum GH levels across multiple routes of administration Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man+1. Peak GH responses are dose-dependent and occur within 15–30 minutes after injection Growth hormone-releasing activity of hexarelin in humans.

Beyond GH, Hexarelin raises prolactin, ACTH, and cortisol. These effects are observed with both single doses and repeated daily administration, indicating a broad pituitary response Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH+2. One sleep study found that nighttime Hexarelin reduced slow-wave sleep while simultaneously boosting GH, ACTH, cortisol, and prolactin Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers.

Preclinical studies suggest additional tissue-protective effects. In animal models, Hexarelin or related peptides have shown cardioprotection after heart attack, improved retinal cell survival, and support for bone density under certain hormonal conditions Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation+2. However, these findings have not been confirmed in human trials.

For body composition or athletic performance, the evidence is weak. While GH secretion is robust, controlled human data linking Hexarelin to muscle gain, fat loss, or recovery are lacking The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1. Most benefits reported in non-medical use are anecdotal and may stem from GH-related water retention rather than true tissue accrual.

Clinical studies have employed a range of dosing schedules. In endocrine testing, single intravenous doses of 0.5–2 µg/kg produce reliable GH release Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man+1. For repeated stimulation, subcutaneous injections of 1 µg/kg two to three times daily have been used in research settings Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.

Community-based protocols often adapt these findings into fixed-dose regimens. A common pattern starts with 100 µg subcutaneously once daily, then increases to twice daily after assessing tolerance. Cycles typically last 6–12 weeks, with periodic breaks to limit receptor adaptation and hormone overload.

Timing matters: injecting in a fasted state may enhance GH response, as food intake can blunt somatotroph sensitivity. Pre-bed dosing can increase nocturnal GH but may disrupt sleep architecture, as seen in the sleep study Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers.

Higher dosing frequency (three times daily) does not proportionately increase GH but significantly raises prolactin and cortisol, so twice-daily is often the practical ceiling to balance effect and side effects Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans+1.

Hexarelin is supplied as a lyophilized powder that must be mixed with a diluent before injection. Bacteriostatic water is the standard choice for multi-dose vials, while sterile water is suitable for immediate use.

To reconstitute, gently inject the diluent down the inner wall of the vial. Avoid shaking, as peptides can degrade under mechanical stress The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Let the powder dissolve with light swirling; the solution should become clear within a few minutes.

Store the dry powder at -20°C for long-term storage or 2–8°C for shorter periods. Once reconstituted, keep the solution refrigerated and protected from light. Peptide stability studies indicate that Hexarelin can form modified species under thermal stress, so avoid prolonged room-temperature exposure and repeated freeze-thaw cycles The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

An interactive calculator is available on this page to help determine appropriate dilution and injection volumes for your specific vial size.

Hexarelin has documented interactions with several hormone-modulating agents. Co-administration with GHRH analogs like sermorelin or tesamorelin can amplify GH release, but this also raises the risk of side effects like edema and elevated prolactin Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH+2.

Glucocorticoids such as dexamethasone can block the ACTH/cortisol response to Hexarelin without affecting GH output Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation. In contrast, arginine can enhance the GH-releasing effect by suppressing somatostatin tone Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study+1.

Benzodiazepines like alprazolam have been shown to blunt both the GH and cortisol responses, indicating that sedatives may reduce Hexarelin's endocrine impact Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation. Somatostatin analogs, including octreotide, partially suppress the GH response, consistent with somatostatin's role in regulating GH secretion Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects to those observed in young adults.

Opioid antagonists (e.g., naloxone) do not appear to interfere with Hexarelin's GH release, suggesting no opioid pathway dependency Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection. For other common supplements like melatonin or glucose-disposal agents, interactions are theoretical but untested.

Hexarelin is often stacked with other GH-axis peptides to enhance pulsatile GH output or extend the half-life of the signal. It synergizes strongly with GHRH analogs (e.g., CJC-1295, sermorelin), as the two agents work via complementary mechanisms—GHSR agonism plus potentiation of endogenous GHRH Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study+1.

Combining Hexarelin with other ghrelin-mimetics like GHRP-2 or ipamorelin is generally redundant, as they compete for the same receptor. Such stacking may simply increase side effects without additive benefit The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.

In recovery-oriented stacks, Hexarelin is occasionally paired with repair peptides like BPC-157 or TB-500. No direct research supports a synergistic effect, but the combination is common in community practice, based on the idea of combining anabolic signaling with tissue healing.

Stacks that include IGF-1 analogs or high-dose GH are considered high-risk due to cumulative fluid retention and potential insulin resistance The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Monitoring is essential when stacking multiple GH-pathway agents.

Hexarelin is not FDA-approved for any medical indication. It remains an investigational compound, with all human data originating from clinical studies rather than therapeutic use The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+2.

In sports, Hexarelin is prohibited at all times under the WADA Prohibited List as a growth hormone secretagogue Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025. Testing methods can detect the parent compound and its metabolites in urine, so short-acting use does not eliminate the risk of a positive test Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Athletes subject to drug testing should assume complete ineligibility for competition while using Hexarelin.

Legally, Hexarelin occupies a grey area in many countries. It is not scheduled as a controlled substance in the US, but as an unapproved drug, its sale for human use is not permitted. It is typically sourced through research chemical vendors, where purity and authenticity are not guaranteed The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.

The most well-documented safety concerns with Hexarelin are hormonal. In multiple studies, it raised prolactin and cortisol levels in a dose- and frequency-dependent manner Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH+2. Chronic elevation of these hormones could lead to side effects like galactorrhea, libido changes, glucose intolerance, and mood disturbances The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

One human study found that nighttime Hexarelin reduced slow-wave sleep and heightened nocturnal pituitary-adrenal activity, which may translate to poorer sleep quality during cycles Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Users often report mild edema, joint stiffness, and transient headaches, consistent with GH excess.

There are no long-term safety trials, so the risks of months-long use remain unknown. Theoretical concerns include acceleration of hormone-sensitive cancers and impaired glucose control The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Regular monitoring of IGF-1, fasting glucose, prolactin, and cortisol is advisable when researching this compound.